AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Kanamycin A sulfate is primarily used to treat bacterial infections caused by susceptible organisms. It works by inhibiting bacterial protein synthesis, thereby preventing bacterial growth and replication.
Respiratory Tract Infections: Kanamycin A sulfate may be used to treat respiratory tract infections, including pneumonia, bronchitis, and bronchiectasis caused by susceptible bacteria. It is particularly effective against gram-negative bacteria.
Urinary Tract Infections: This antibiotic can be prescribed for the treatment of urinary tract infections caused by susceptible organisms, such as Escherichia coli, Proteus species, and Klebsiella pneumoniae.
Intra-abdominal Infections: Kanamycin A sulfate may be used as part of the treatment regimen for intra-abdominal infections, including peritonitis and intra-abdominal abscesses, especially in cases where other antibiotics are ineffective or contraindicated.
Skin and Soft Tissue Infections: Kanamycin A sulfate may be used to treat skin and soft tissue infections caused by susceptible bacteria, such as cellulitis, abscesses, and infected wounds.
Eye Infections: Ophthalmic preparations of kanamycin A sulfate are available for the treatment of eye infections, including bacterial conjunctivitis and keratitis caused by susceptible organisms.
Tuberculosis: Kanamycin A sulfate is sometimes used as part of combination therapy for the treatment of drug-resistant tuberculosis, particularly in cases where other first-line and second-line tuberculosis drugs are ineffective.
Cystic Fibrosis: In patients with cystic fibrosis, kanamycin A sulfate may be used to treat chronic respiratory infections caused by Pseudomonas aeruginosa and other bacteria commonly associated with the condition.
Hospital-acquired Infections: Kanamycin A sulfate may be used in hospitals to treat infections caused by multidrug-resistant bacteria, including those acquired in healthcare settings.
Adverse Effects: Common side effects associated with kanamycin A sulfate include nephrotoxicity (kidney damage), ototoxicity (hearing loss or vestibular dysfunction), and neurotoxicity (central nervous system effects). Monitoring of kidney function and hearing is necessary during treatment.
Resistance: The emergence of bacterial resistance to kanamycin A sulfate is a concern with prolonged or inappropriate use. Resistance monitoring and prudent antibiotic use are essential to mitigate the development of resistant bacterial strains.
Pregnancy and Lactation: Kanamycin A sulfate is generally considered safe for use during pregnancy and lactation when the benefits outweigh the risks. However, healthcare providers should weigh the potential risks and benefits before prescribing kanamycin A sulfate to pregnant or breastfeeding women.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.9 | 0.9 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.3 | 1 |
| Allergies | 0.3 | 0.6 | -1 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 1.1 | 1.7 | -0.55 |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 0.3 | 0.9 | -2 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 1.1 | 0.6 | 0.83 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 0.9 | 1.2 | -0.33 |
| Autism | 1 | 1.8 | -0.8 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.6 | 0.6 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0 | 0 |
| Carcinoma | 1.4 | 0.3 | 3.67 |
| Celiac Disease | 0.6 | 0.6 | 0 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 0.9 | 1.3 | -0.44 |
| Chronic Kidney Disease | 0.4 | 1 | -1.5 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.6 | 0.5 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 1.6 | 0.6 | 1.67 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.6 | 0.9 | -0.5 |
| COVID-19 | 1.2 | 2.1 | -0.75 |
| Crohn's Disease | 1.4 | 1.2 | 0.17 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.2 | 0.6 | -2 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 1.3 | 1.5 | -0.15 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 0.6 | 0.6 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.4 | 0.3 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.4 | 0.5 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 1.1 | 0.3 | 2.67 |
| Hashimoto's thyroiditis | 0.7 | 0.7 | 0 |
| Heart Failure | 0.8 | 0.6 | 0.33 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| hyperglycemia | 0.3 | 0.3 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.7 | 0.9 | -0.29 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | |
| Inflammatory Bowel Disease | 1.7 | 1.9 | -0.12 |
| Insomnia | 0.9 | 0.9 | 0 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.9 | 0.6 | 0.5 |
| ischemic stroke | 0.6 | 0.6 | 0 |
| Liver Cirrhosis | 1.7 | 1.2 | 0.42 |
| Long COVID | 1.5 | 1.2 | 0.25 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.5 | 0.5 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.3 | 1.2 | 0.08 |
| Mood Disorders | 1.2 | 1.5 | -0.25 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.1 | 1.2 | -0.09 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.9 | 0.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.3 | 1.4 | -0.08 |
| obsessive-compulsive disorder | 0.6 | 1 | -0.67 |
| Osteoarthritis | 1 | 0.6 | 0.67 |
| Osteoporosis | 0.3 | 0.6 | -1 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 1.3 | 2.2 | -0.69 |
| Polycystic ovary syndrome | 0.9 | 0.9 | 0 |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.9 | 0.9 | |
| Psoriasis | 0.3 | 0.9 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 1.2 | -0.09 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 1.2 | 0.3 | 3 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.3 | 0.6 | -1 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.3 | 1 |
| Systemic Lupus Erythematosus | 1.2 | 0.1 | 11 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 0.9 | 0.6 | 0.5 |
| Type 2 Diabetes | 1.4 | 0.9 | 0.56 |
| Ulcerative colitis | 1.2 | 0.6 | 1 |
| Unhealthy Ageing | 1.5 | 0.6 | 1.5 |
| Vitiligo | 0.6 | 0.6 |
